Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + LX4211
- Development stage
- Unknown
- Lead developer
- Lexicon Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rosuvastatin + LX4211 is a combination of two small molecule drugs with distinct mechanisms of action. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce the risk of cardiovascular events by inhibiting cholesterol biosynthesis in the liver, leading to decreased LDL and triglycerides and increased HDL levels. LX4211 is a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/SGLT2), developed for glycemic control in diabetes; it lowers blood glucose by reducing renal glucose reabsorption (via SGLT2 inhibition) and delaying intestinal glucose absorption (via SGLT1 inhibition). The combination could theoretically address both dyslipidemia and hyperglycemia, though there are no approved fixed-dose combinations or clinical evidence supporting their combined use as a single product.
- Brand names
- CrestorEzallor SprinkleRoszet
- Other names
- rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on rosuvastatin + LX4211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + LX4211.